1
|
Meinhardt AL, McPherson M, Berg C, Cai D, Blumenfrucht M, Chang V, Zhong F. PP01.69 NSCLC with Testicular Metastasis: A Case Report. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
2
|
Kasimis B, Chang VT, Gonzalez ML, Srinivas S, Zhong F, Duque L, McPherson M, Einhorn J, Crump B, Blumenfrucht M. The Gleason score (GS) as a predictor of survival in stage D2 and D3 prostate cancer (PC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, Srinivas S, Cogswell J, Morales E, Ahmed S. Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16019 Background: Several signal transduction pathways,important for apoptosis and angiogenesis were idendified and their expression and correlation with survival was studied by IHC in archival prostate cancer biopsies. All pts has androgen deprivation for stage D2 disease and were followed at 3 month intervals. Methods: In an IRB approved study,42 pts had adequate tissue preserved between 1992 and 2006 and their charts were reviewed retrospectively.IHC stains to detect tumor expression of S6(ribosomal),p70s6,pTEN,AKT-1,BCL-1(Cyclin D1),VEGF,c-KIT,PDGFR-alpha and PDGFR-beta were performed by US Labs(Irvine,CA).All results were independently evaluated by two pathologists.Immunoreactivity was scored using a semiquantitative system combining intensity of staining(0–3+) and percentage of cells staining positive(0–3+).The total score was obtained by adding the scores for indensity and the percentage of positive cells,then averaging the resuts obtained by each reader.For the purpose of this study, stain intensity of 0–1+ was considered negative and the intensity of 2–3+ was considered positive.A Cox regression survival model for each stain was developed with variables known to predict survival :Gleason score,Hemoglobin(Hgb),Alkaline Phosphatase(Alk Phos),Prostate Specific Antigen(PSA),Lactate Dehydrogenase(LDH) levels. Results: The median values were: age 70yrs(56–92),Gleason score 8(6–10), LDH 171 IU/L(97–350),Hgb 12.9gm/dl (6.8–16.3), PSA 188ng/ml(2–5677),Alk Phos 139U/L(60–1756),survival 851 days(163- 6102).In univariate analysis,VEGF staining was predictive of survival (p<0.037) but not in multivariate analysis.The pTEN staining correlated with survival (p<0.0367) and a hazard ratio of 0.040 in multivariate analysis. Conclusions: In this small sample of pts, overexpression of S6,p70s6,AKT-1,BCL-1,VEGF,c-KIT,PDGFR-alpha and PDGFR-beta by IHC staining did not predict survival independently.The pTEN staining,however was strong predictor of survival in the multivariate analysis. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Kasimis
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - V. Chang
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - S. Gounder
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - M. Gonzalez
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - C. Finch-Cruz
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - M. Blumenfrucht
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - S. Srinivas
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - J. Cogswell
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - E. Morales
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| | - S. Ahmed
- New Jersey Medical School/VANJHCS, East Orange, NJ; New Jersey Medical School/VANJHCS, Newark, NJ; VANJHCS, East Orange, NJ
| |
Collapse
|
4
|
Kasimis BS, Chang V, Gounder S, Hoover D, Finch-Cruz C, Cogswell J, Gonzalez ML, Morales E, Srinivas S, Blumenfrucht M. Correlation between prostate cancer immunohistochemical stains (IHC) and survival in stage D2 patients(pts). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Kasimis B, Chang VT, Hoover D, Sikder M, Gounder S, Finch Cruz C, Gonzalez ML, Cogswell J, Srinivas S, Blumenfrucht M. VEGF, PDGF alpha, PDGF beta, and C-Kit expression are not independent survival predictors in stage D 2 prostate cancer (PC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15623 Background: In PC, overexpression of VEGF, PDGF alpha, PDGF beta, and C-Kit has been reported in over 50% of biopsy samples and may be important predictors of survival. Methods: In an ongoing project, we reviewed the records of 26 patients (pts) with stage D2 PC and stained their archival tissue specimens for VEGF, PDGF alpha, PDGF beta, and C-Kit expression. Immunohistochemistry was performed at US LABS (Irvine CA). All immunostains were evaluated by two pathologists. Immunoreactivity was scored using a semiquantitative system for intensity of staining (0–3+) and % of tumor cells (0–3+). The total score was obtained by averaging the scores between the two readers. All pts had androgen deprivation and were followed at 3 months intervals with physical examination, CBC, chemistry profile and PSA levels. A stepwise Cox model was used with variables: Gleason score, Hemoglobin (Hgb), Alkaline Phosphatase (Alk Phos), PSA, LDH levels, and C-Kit positive or negative staining. Results: Median values were as follows: age 69 years (56–91), Alk Phos 139 U/L(60–1298), PSA 178 ng/ml (1.8–5677), LDH 169 IU/L (100–350), Hgb 12.8 gm/dl (6.8–16.3), Gleason score 8 (5–10), Survival 26 mos (8.3–144.1). The median value for C-Kit staining was 3 on a scale of 0–6. 18 pts were grouped into low staining group (0–4) and 8 pts in a high staining group (4.5–5). The Kappa Coefficient for C-Kit was 0.83, and ranged from 0.78–0.91 for the other 3 stains. In univariate survival analyses, C-Kit staining was a predictor for survival (p=0.037) but not PDGF alfa, PDGF beta, or VEGF. In the stepwise Cox model, independent survival predictors in order of significance were the Gleason score, Hgb, and PSA levels. Conclusions: In this sample, VEGF, PDGF alpha, PDGF beta, and C-Kit overexpression by immunohistochemistry in archival tissue are not independent predictors of survival. The C-Kit, however, has a small association with survival but may have collinearity with known predictors of survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Kasimis
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - V. T. Chang
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - D. Hoover
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - M. Sikder
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - S. Gounder
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - C. Finch Cruz
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - M. L. Gonzalez
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - J. Cogswell
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - S. Srinivas
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| | - M. Blumenfrucht
- University of Medicine and Dentistry of New Jersey, Newark, NJ; VA New Jersey Health Care System, East Orange, NJ; Rutgers University, New Brunswick, NJ
| |
Collapse
|
6
|
Zhong F, Kasimis B, Chang V, Sambamoorthi N, Srinivas S, Cogswell J, Morales E, Gonzalez M, Duque L, Blumenfrucht M. A phase II trial of epirubicin (E), estramustine phosphate (EP), and celecoxib (C) as second line treatment of patients (pts) with hormone resistant prostate cancer (HRPC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14567] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14567 Background: Celecoxib, epirubicin, and estramustine phosphate affect prostate cancer cells through different mechanisms. All three could be synergistic. We studied the effects of this combination on PSA, response, toxicity and survival in pts with HRPC. Methods: Pts after progression from first line taxane-based chemotherapy with rising PSA and radiographic progression were eligible. Treatment was E30 mg/m2 iv on day 1 and 8 of each 4 week cycle; EP 280 mg po bid daily × 3 days every wk × 2 followed by 2 wks rest; C 400 mg po bid daily for 28 days. All pts were assessed for response every 2 cycles. Dose modifications for hematologic and hepatorenal toxicity were made. RECIST criteria and PSA decline>50% were used to define response. Results: Sixteen pts enrolled, and 13 are evaluable for toxicity and response. Two withdrew before treatment and one for toxicity. The Median (M) age was 71.5 yrs (59–87), ECOG PS 1 (0–1), Gleason score 7 (4–9), LDH 172 (131–244), Hgb 11.1 (8.8–11.9), PSA 75 (6–814). Pts received M 4 cycles (2–10). Nine (69%) pts had soft tissue and 12 (92%) pts had bone metastases. For radiographic response, 11 pts were evaluable; 6 had stable disease and 2 had complete response by CT. Two pts had response by bone scan. Nine (69%) pts had PSA response. The M survival was 441 days (10–995). There were 5 SAE - DVT, diarrhea, bowel obstruction, cord compression and myocardial infarction. There was good renal and cardiac tolerance. Conclusions: This combination was safe and showed good and durable response as a second line regimen. [Table: see text]
Collapse
Affiliation(s)
- F. Zhong
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - B. Kasimis
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - V. Chang
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - N. Sambamoorthi
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - S. Srinivas
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - J. Cogswell
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - E. Morales
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - M. Gonzalez
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - L. Duque
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - M. Blumenfrucht
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| |
Collapse
|
7
|
Kasimis B, Chang V, Cogswell J, Sambamoorthi N, Gonzalez M, Srinivas S, Zhong F, Morales E, Duque L, Blumenfrucht M. Combination therapy with docetaxel (D) and celecoxib (C) in patients (pts) with hormone resistant prostate cancer (HRPC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14519] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14519 Background: Cox-2 expression is an independent predictor of survival and is over expressed in 89.3% of pts with HRPC. Cox-2 expression has angiogenic and cytoprotective effects. Its suppression could lead to angiogenesis inhibition and increase chemotherapy sensitivity. D in low doses and C are angiogenesis inhibitors. The main objectives were to study the effects on PSA, time to progression (TTP), toxicity and survival. Methods: In a two stage, phase II trial designed for 66 pts, 30 pts with HRPC and evidence of biochemical and radiographic progression were treated with D 30 mg/m2 IV/wk for 3 wks and C 400 mg po bid for 4 wks of each cycle. Response evaluation after every two cycles was made. RECIST criteria and PSA reduction by >50% for biochemical response were used. Independent safety monitoring for renal (R) and cardiovascular (CV) toxicity were made. Results: Thirty (30) evaluable pts received minimum of 2 cycles, median (M) 4.5 (range 2–8). The M age was 74 yr (55–94), ECOG PS 1 (0–2), Hb 11.8 g/dl (8.6–14.6), and PSA 92.5 ng/dl (15.3–4192). Metastases were present in 24 pts (80%) by bone scan and 25 pts (83.3%) by CT scan. Twelve (12) pts (40%) had PSA response of >50% and 4 pts (13.3%) had PSA normalization. By CAT scan, 3 pts (10%) had CR, 5 pts (16.7%) had PR, and 12 pts (40%) had SD. By bone scan 1 pt (4.8%) had a major response. The M TTP by PSA was 3.65 mos (0.87–12.0). With 27% pts still alive, the M survival was 10.9 mos (3.0– 30.7+), with 95% CI for the mean (9.3–15.2). One pt (3.3%) withdrew due to abdominal discomfort, 2 pts (6.6%) had grade III diarrhea and 1 pt (3.3%) had grade III nail toxicity. Conclusions: 66.7% pts had soft tissue response (CR+PR+SD), and 13.3% pts had PSA normalization. Safety analysis for R and CV toxicity demonstrated excellent safety of this regimen. Considering the unfavorable prognostic indicators of this population the MST of 10.9 mos indicates the activity of this combination. [Table: see text]
Collapse
Affiliation(s)
- B. Kasimis
- VA New Jersey Health Care System, East Orange, NJ
| | - V. Chang
- VA New Jersey Health Care System, East Orange, NJ
| | - J. Cogswell
- VA New Jersey Health Care System, East Orange, NJ
| | | | - M. Gonzalez
- VA New Jersey Health Care System, East Orange, NJ
| | - S. Srinivas
- VA New Jersey Health Care System, East Orange, NJ
| | - F. Zhong
- VA New Jersey Health Care System, East Orange, NJ
| | - E. Morales
- VA New Jersey Health Care System, East Orange, NJ
| | - L. Duque
- VA New Jersey Health Care System, East Orange, NJ
| | | |
Collapse
|
8
|
Chang VT, Sambamoorthi N, Yan H, Gonzalez M, Cogswell J, Srinivas S, Zhong F, Crump B, Blumenfrucht M, Kasimis BS. Quality of life (QOL) in patients (Pts) with hormone resistant prostate cancer (HRPC) treated with docetaxel (D) and celecoxib (C). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18598 Background: The impact of chemotherapy on QOL for pts with HRPC is not well described. Thirty patients(30) participated in a trial of D and C(Kasimis et al, submitted ASCO 2006). The objectives for this companion study were to study QOL outcomes with the FACT instrument including the Prostate subscale(FP) and utility from the EQ5D. Methods: In a phase II trial, 30 pts with progressive HRPC were treated with D and C for 4 wks in each cycle. Response evaluation was made by RECIST criteria and PSA reduction by >50% for biochemical response every 2 cycles. Patients completed the FACT and EQ5D instruments at the beginning of every cycle. We analyzed the FACT subscales with different statistical approaches, and compared FACT and utility for responders and non responders. Results: All 30 pts accrued were evaluable for toxicity and response. Thirty (30) pts received a minimum of 2 cycles, median (M) 4.5 (range 2–8). The M age was 74 yr (55–94), ECOG PS 1 (0–2). For 19 pts, the baseline mean score for the FACT P was 29, Standard Deviation 10. The Cronbach’s Coefficient was 0.83. The FACT Physical Well Being (PWB) correlated with the EQ5D utility score 0.76 (p < .0003), as did the Functional Well Being (FWB) 0.67 (p < .003) and FACT P 0.62 (p < .006). The FACT PWB, EWB, FP, Treatment Outcome Index, and EQ5D Utility differed significantly between responders and non responders by radiographic parameters, alpha = 0.1. The results for PSA reduction >50% are similar. Conclusions: The FACT Prostate subscale has good psychometric properties, correlates with EQ5D utility measure, and also with responder status by radiography and PSA. [Table: see text]
Collapse
Affiliation(s)
- V. T. Chang
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - N. Sambamoorthi
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - H. Yan
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - M. Gonzalez
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - J. Cogswell
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - S. Srinivas
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - F. Zhong
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - B. Crump
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - M. Blumenfrucht
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| | - B. S. Kasimis
- VA New Jersey Health Care System, East Orange, NJ; CRMportals, Inc., Englishtown, NJ
| |
Collapse
|
9
|
Kasimis B, Cogswell J, Hwang S, Chang VT, Srinivas S, Zhong F, Duque L, Morales E, Boholli I, Blumenfrucht M. High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4704] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Kasimis
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - J. Cogswell
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - S. Hwang
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - V. T. Chang
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - S. Srinivas
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - F. Zhong
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - L. Duque
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - E. Morales
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - I. Boholli
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| | - M. Blumenfrucht
- VA NJ Health Care System, East Orange, NJ; VA New Jersey Health Care System, East Orange, NJ; VA New Jersey Health Care System/UMDNJ, East Orange, NJ
| |
Collapse
|
10
|
Zhong F, Kasimis B, Hwang S, Cogswell J, Chang V, Morales E, Gonzalez M, Boholli I, Ohanian M, Blumenfrucht M. Second line treatment of hormone resistant prostate cancer (HRPC). A phase II trial of epirubicin (E), estramustine phosphate (EP) and celecoxib (C). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4754] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Zhong
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - B. Kasimis
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - S. Hwang
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - J. Cogswell
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - V. Chang
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - E. Morales
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - M. Gonzalez
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - I. Boholli
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - M. Ohanian
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| | - M. Blumenfrucht
- VA NJ Healthcare System/NJ Medcl Sch, UMDNJ, East Orange, NJ
| |
Collapse
|
11
|
Kasimis B, Cogswell J, Hwang S, Chang V, Llorente M, Boholli I, Srinivas S, Morales E, Davis C, Blumenfrucht M. Phase II trial of docetaxel (D) and high-dose celecoxib (C) in patients (Pts) with hormone resistant prostate cancer (HRPC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Kasimis
- VA NJ Health Care System, East Orange, NJ
| | | | - S. Hwang
- VA NJ Health Care System, East Orange, NJ
| | - V. Chang
- VA NJ Health Care System, East Orange, NJ
| | | | - I. Boholli
- VA NJ Health Care System, East Orange, NJ
| | | | - E. Morales
- VA NJ Health Care System, East Orange, NJ
| | - C. Davis
- VA NJ Health Care System, East Orange, NJ
| | | |
Collapse
|
12
|
Kasimis B, Wilding G, Kreis W, Feuerman M, Chang V, Hwang S, Steafather H, Cogswell J, Rae C, Blumenfrucht M. Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer. Cancer Invest 2001; 18:602-8. [PMID: 11036467 DOI: 10.3109/07357900009032826] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Patients with hormone-naive stage D2 prostate cancer often benefit from castration. This treatment, however, frequently produces many unacceptable physical and psychological side effects, especially in younger and sexually active patients. Bicalutamide is an oral antiandrogen with excellent tolerance and preservation of sexual function. Three institutions participated in phase II and III trials of bicalutamide monotherapy (50 mg daily) as primary therapy in hormone-naive patients with stage D2 prostate cancer. Upon bicalutamide failure, all patients underwent castration and were followed until death. Fifty-four patients received bicalutamide 50 mg orally once a day. One patient (2%) had complete response, 9 patients (17%) had partial response, and 27 patients (50%) had stable disease. Seventeen patients (31%) had progressive disease. The median time to bicalutamide failure was 47.4 weeks, 70.5 weeks for the responders vs. 25.4 weeks for the nonresponders (p < 0.001). The median survival time after the sequential use of bicalutamide and castration was 119.2 weeks for all 54 patients, 162.0 weeks for the responders, and 73.5 weeks for nonresponders (p < 0.0001). The median survival time after initiation of castration was 71.1 weeks for all 54 patients, 91.4 weeks for bicalutamide responders, and 42.1 weeks for nonresponders (p < 0.01). In hormone-naive patients with stage D2 prostate cancer, sequential treatment with bicalutamide monotherapy followed by castration upon failure may produce survival time within the range reported for initial treatment with castration. Thus, considering the favorable quality of life profile of bicalutamide, further studies are needed to define the role of sequential hormonal therapy in younger sexually active patients.
Collapse
Affiliation(s)
- B Kasimis
- Section of Hematology/Oncology, Department of Veterans Affairs New Jersey Health Care Systems, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Ten male dogs underwent segmental excision of tunica albuginea of corpus cavernosum penis and replacement with polytetrafluoroethylene grafts. None of the dogs exhibited acute or chronic adverse reaction to the graft. These findings suggest that PTFE may have a role in human reconstructive phalloplasty.
Collapse
|